These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1535591)

  • 1. Pharmacokinetics of nicorandil in patients with normal and impaired renal function.
    Molinaro M; Villa G; Regazzi MB; Salvadeo A; Segagni S; Rondanelli R; Sartirana E
    Eur J Clin Pharmacol; 1992; 42(2):203-7. PubMed ID: 1535591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of nicorandil in patients with congestive heart failure.
    Tice FD; Jungbluth GL; Binkley PF; MacKichan JJ; Mohrland JS; Wolf DL; Leier CV
    Clin Pharmacol Ther; 1992 Nov; 52(5):496-503. PubMed ID: 1424424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs.
    Ishizaki T; Chiba K; Suganuma T; Sasaki T; Kamiyama H; Nakano H
    J Pharm Sci; 1984 Apr; 73(4):494-8. PubMed ID: 6233416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of nicorandil.
    Frydman AM; Chapelle P; Diekmann H; Bruno R; Thebault JJ; Bouthier J; Caplain H; Ungethuem W; Gaillard C; Le Liboux A
    Am J Cardiol; 1989 Jun; 63(21):25J-33J. PubMed ID: 2525322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic profile of nicorandil in humans: an overview.
    Frydman A
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S34-44. PubMed ID: 1282174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.
    Wolf DL; Ferry JJ; Hearron AE; Froeschke MO; Luderer JR
    Eur J Clin Pharmacol; 1993; 44(1):27-33. PubMed ID: 8436151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain.
    Arnold JM; Kowey PR; Wolf DL; Jungbluth GL; Hearron AE; Luderer JR
    Int J Cardiol; 1994 May; 44(3):203-15. PubMed ID: 8077066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic method for stability and pharmacokinetic studies of nicorandil.
    Bachert EL; Fung HL
    J Chromatogr; 1993 Sep; 619(2):336-41. PubMed ID: 8263109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of increasing doses of nicorandil on renal function in man.
    Wolf DL; Jungbluth GL; Metzler CM; Froeschke MO; DeLoof MJ; Luderer JR
    Int J Clin Pharmacol Ther; 1994 May; 32(5):246-53. PubMed ID: 7921519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
    Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.
    Camm AJ; Maltz MB
    Am J Cardiol; 1989 Jun; 63(21):61J-65J. PubMed ID: 2525328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris.
    Meany TB; Richardson P; Camm AJ; Coltart J; Griffith M; Maltz MB; Signy M
    Am J Cardiol; 1989 Jun; 63(21):66J-70J. PubMed ID: 2525329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of footshock stress on pharmacokinetics of nicorandil in rats.
    Yamori M; Gomita Y; Oishi R
    Life Sci; 1991; 48(21):2065-73. PubMed ID: 1827856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
    Frampton J; Buckley MM; Fitton A
    Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina.
    Chen JW; Lee WL; Hsu NW; Lin SJ; Ting CT; Wang SP; Chang MS
    Am J Cardiol; 1997 Jul; 80(1):32-8. PubMed ID: 9205016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified product inhibition model describes the nonlinear pharmacokinetics of nicorandil in rats.
    Bachert EL; Li ZW; Zhao L; Chung SJ; Fung HL
    Pharm Res; 1994 Aug; 11(8):1190-8. PubMed ID: 7971723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effects of oral nicorandil in congestive heart failure.
    Tice FD; Binkley PF; Cody RJ; Moeschberger ML; Mohrland JS; Wolf DL; Leier CV
    Am J Cardiol; 1990 Jun; 65(20):1361-7. PubMed ID: 2140489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorimetric determination of nicorandil in human plasma by a high-performance liquid chromatographic-postcolumn ultraviolet irradiation [corrected] system equipped with on-line back-pressure tubing.
    Mawatari K; Nakamura Y; Shimizu R; Sate S; Iinuma F; Watanabe M
    J Chromatogr B Biomed Appl; 1996 Apr; 679(1-2):155-9. PubMed ID: 8998555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.